Key Takeaways

In this randomized trial, dalbavancin didn't result in improved outcomes versus standard treatment for adults with complicated Staphylococcus aureus bacteremia.

Rates of adverse events leading to treatment discontinuation were numerically more frequent in the standard therapy group.

Despite missing superiority, dalbavancin may give patients and doctors another treatment option, researchers said.

Dalbavancin (Dalvance) didn't deliver better overall outcomes compared with standard treatment in adults with complicated Staphylococcus aureus bacteremia, a randomized trial showed.

Among 200 patients, the probability of a more desirable day-70 outcome with two doses of intravenous dalbavancin versus 4 to 8 total weeks of standard therapy with an intravenous antibiotic was 4

See Full Page